InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,180.74
(
1.03%
)
US TECH 100
17,598.80
(
1.03%
)
Dow Jones
38,852.27
(
0.46%
)
Brent Oil
83.30
(
-0.22%
)
Bitcoin
63,504.57
(
0.54%
)
Post# of 6070
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

operating_line

Send PM Follow Ignore
Followers 8
Posts 921
Boards Moderated 0
Alias Born 10/07/2015

operating_line

Re: None

Saturday, 09/29/2018 12:44:41 AM

Saturday, September 29, 2018 12:44:41 AM

Post# of 6070
CASI funding and new CFO

"to help transition the Company's financial operations to commercial stage as we launch EVOMELA® and other additional products from our pipeline

https://www.gurufocus.com/news/746156/casi-pharmaceuticals-announces-appointment-of-chief-financial-officer

https://www.marketwatch.com/press-release/casi-pharmaceuticals-announces-485-million-private-placement-2018-09-14

Summary of status with Marqibo

Highest Development Phases
Marketed Precursor cell lymphoblastic leukaemia-lymphoma
Phase III Non-Hodgkin's lymphoma
Phase I/II Cancer
Preclinical Multiple myeloma
Discontinued Colorectal cancer; Malignant melanoma; Pancreatic cancer; Small cell lung cancer

Most Recent Events
14 Aug 2018 CASI Pharmaceuticals expects that the CFDA will complete the review of Marqibo’s import drug clinical trial application within the next four to six months
24 Jun 2018 Biomarkers information updated
26 May 2017 Phase II development for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) is ongoing in USA
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up